Albumin-bound paclitaxel: a next-generation taxane

Bibliography

• WANI MC, TAYLOR HL, WALL ME et al.: Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 93:2325-2327.
   PubMed Web of Science ®Google Scholar
• SCHIFF PB, HOROWITZ SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA (1980) 77:1561-1565.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, CAZENAVE LA, DONEHOWER RC: Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. (1990) 82:1247-1259.
   PubMed Web of Science ®Google Scholar
• SCHIFF PB, FANT J, HORWITZ SB: Promotion of microtubule assembly in vitro by Taxol. Nature (1979) 277:665-667.
   PubMed Web of Science ®Google Scholar
• BRISTOL-MYERS SQUIBB CO.: Taxol® (paclitaxel) injection prescribing information. Bristol-Myers Squibb Co., Princeton (NJ) USA (2003).
   Google Scholar
• AVENTIS PHARMACEUTICAL PRODUCTS, INC.: Taxotere® (docetaxel) injection prescribing information. Aventis Pharmaceutical Products, Inc. Bridgewater (NJ) USA (2002).
   Google Scholar
• DYE D, WATKINS J: Suspected anaphylactic reaction to Cremophor EL. Br. Med. J. (1980) 280:1353.
   PubMed Web of Science ®Google Scholar
• GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 37:1590-1598.
   PubMed Web of Science ®Google Scholar
• WEISS RB, DONEHOWER RC, WIERNIK PH et al.: Hypersensitivity reactions from Taxol. J. Clin. Oncol. (1990) 8:1263-1268.
   PubMed Web of Science ®Google Scholar
• VOLCHECK GW, VAN DELLEN RG: Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann. Allergy Asthma Immunol. (1998) 80:159-163.
   PubMed Web of Science ®Google Scholar
• KLOOVER JS, DEN BAKKER MA, GELDERBLOM H et al.: Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br. J. Cancer (2004) 90:304-305.
   PubMed Web of Science ®Google Scholar
• TEN TIJE AJ, VERWEIJ J, LOOS WJ, SPARREBOOM A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. (2003) 42:665-685.
   PubMed Web of Science ®Google Scholar
• GIANNI L, KEARNS CM, GIANI A et al.: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacodynamic relationships in humans. J. Clin. Oncol. (1995) 13:180-190.
   PubMed Web of Science ®Google Scholar
• WEBSTER LK, COSSON EJ, STOKES KH, MILLWARD MJ: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer (1996) 73:522-524.
   PubMed Web of Science ®Google Scholar
• MILLWARD MJU, WEBSTER LK, RISCHIN D et al.: Phase I trial of Cremophor EL with bolus doxorubicin. Clin. Cancer Res. (1998) 4:2321-2329.
   PubMedGoogle Scholar
• HOLMES FA, ROWINSKY EK: Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin. Oncol. (2001) 28(Suppl. 12):8-14.
   PubMed Web of Science ®Google Scholar
• HOLMES FA, MADDEN T, NEWMAN RA et al.: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. (1996) 14:2713-2721.
   PubMed Web of Science ®Google Scholar
• AUTHIER N, GILLET J-P, FIALIP J, ESCHALIER A, COUDORE F: Description of a short-term Taxol® -induced nociceptive neuropathy in rats. Brain. Res. (2000) 887:239-249.
   PubMed Web of Science ®Google Scholar
• AUTHIER N, GILLET JP, FIALIP J, ESCHALIER A, COUDORE F: Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox. Res. (2001) 3:301-306.
   PubMed Web of Science ®Google Scholar
• LORENZ W, SCHMAL A, SCHULT H et al.: Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in Cremophor EL and development of a compound with reduced toxicity. Agents Actions (1982) 12:64-80.
   PubMedGoogle Scholar
• WINDEBANK AJ, BLEXRUD MD, DE GROEN PC: Potential neurotoxicity of the solvent vehicle for cyclosporine. J. Pharmacol. Exp. Ther. (1994) 268:1051-1056.
   PubMed Web of Science ®Google Scholar
• SPARREBOOM A, VAN ZUYLEN L, BROUWER E et al.: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. (1999) 59:1454-1457.
   PubMed Web of Science ®Google Scholar
• BROUWER E, VERWEIJ J, DE BRUIJN P et al.: Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos. (2000) 28:1141-1145.
   PubMed Web of Science ®Google Scholar
• VAN TELLINGEN O, HUIZING MT, PANDAY VRN et al.: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer (1999) 81:330-335.
   PubMed Web of Science ®Google Scholar
• WINER EP, BERRY DA, SOOLF S et al.: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J. Clin. Oncol. (2004) 22:2061-2068.
   PubMed Web of Science ®Google Scholar
• HERVE F, URIEN S, ALBENGRES E, DUCHE JC, TILLEMENT JP: Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin. Pharmacokinet. (1994) 26:44-58.
   PubMed Web of Science ®Google Scholar
• CURRY S, MANDELKOW H, BRICK P, FRANKS N: Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nature Struct. Biol. (1998) 5:827-835.
   PubMed Web of Science ®Google Scholar
• COLMENAREJO G: In silico prediction of drug-binding strengths to human serum albumin. Med. Res. Rev. (2003) 23:275-301.
   PubMed Web of Science ®Google Scholar
• FEHSKE KJ, MULLER WE, WOLLERT U: The location of drug binding sites in human serum albumin. Biochem. Pharmacol. (1981) 30:687-692.
   PubMed Web of Science ®Google Scholar
• VORUM H, FISKER K, HONORE B: Palmitate and stearate binding to human serum albumin. Determination of relative binding constants. J. Pept. Res. (1997) 49:347-354.
   PubMedGoogle Scholar
• PURCELL M, NEAULT JF, TAJMIR-RIAHI HA: Interaction of taxol with human serum albumin. Biochem. Biophys. Acta. (2000) 1478:61-68.
   PubMed Web of Science ®Google Scholar
• PAÁL K, MÜLLER J, HEGEDÛS L: High affinity binding of paclitaxel to human serum albumin. Eur. J. Biochem. (2001) 268:2187-2191.
   PubMedGoogle Scholar
• MAKRIYANNIS A, GUO J, TIAN X: Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. Life Sci. (2005) 77:1605-1611.
   PubMedGoogle Scholar
• JOHN TA, VOGEL SM, TIRUPPATHI C et al.: Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell. Mol. Physiol. (2003) 284:L187-L196.
   PubMed Web of Science ®Google Scholar
• MINSHALL RD, TIRUPPATHI C, VOGEL SM, MALIK AB: Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem. Cell Biol. (2002) 117:105-112.
   PubMed Web of Science ®Google Scholar
• VOGEL SM, MINSHALL RD, PILIPOVIC M, TIRUPPATHI C, MALIK AB: Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am. J. Physiol. Lung. Cell Mol. Physiol. (2001) 281:L1512-L1522.
   PubMed Web of Science ®Google Scholar
• SIMIONESCU M, GAFENCU A, ANTOHE F: Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc. Res. Tech. (2002) 57:269-288.
   PubMed Web of Science ®Google Scholar
• SCHNITZER JE, OH P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J. Biol. Chem. (1994) 269:6072-6082.
   PubMed Web of Science ®Google Scholar
• CARVER LA, SCHNITZER JE: Caveolae: mining little caves for new cancer targets. Nat. Rev. Cancer. (2003) 3:571-581.
   PubMed Web of Science ®Google Scholar
• DESAI N, TRIEU V, YAO Z et al.: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. (2006) 12:1317-1324.
   PubMed Web of Science ®Google Scholar
• FRAMSON PE, SAGE EH: SPARC and tumor growth: where the seed meets the soil? J. Cell Biochem. (2004) 92:679-690.
   PubMed Web of Science ®Google Scholar
• GOLDBLUM SE, DING X, FUNK SE, SAGE EH: SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc. Natl. Acad. Sci. USA (1994) 91:3448-3452.
   PubMed Web of Science ®Google Scholar
• SCHIEMANN BJ, NEIL JR, SCHIEMANN WP: SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Molec. Biol. Cell. (2003) 14:3977-3988.
   PubMed Web of Science ®Google Scholar
• KOBLINSKI JE, KAPLAN-SINGER BR, VANOSDOL SJ et al.: Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res. (2005) 65:7370-7377.
   PubMed Web of Science ®Google Scholar
• BRIGGS J, CHAMBOREDON S, CASTELLAZZI M, KERRY JA, BOS TJ: Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene (2002) 21:7077-7091.
   PubMed Web of Science ®Google Scholar
• GILLES C, BASSUK JA, PULYAEVA H, SAGE EH, FOIDART JM, THOMPSON EW: SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. (1998) 58:5529-5536.
   PubMed Web of Science ®Google Scholar
• KOUKOURAKIS MI, GIATROMANOLAKI A, BREKKEN RA et al.: Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. (2003) 63:5376-5380.
   PubMed Web of Science ®Google Scholar
• THOMAS R, TRUE LD, BASSUK JA, LANGE PH, VESSELLA RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. (2000) 6:1140-1149.
   PubMed Web of Science ®Google Scholar
• LEDDA F, BRAVO AI, ADRIS S, BOVER L, MORDOH J, PODHAJCER OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. (1997) 108:210-214.
   PubMed Web of Science ®Google Scholar
• JONES C, MACKAY A, GRIGORIADIS A et al.: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. (2004) 64:3037-3045.
   PubMedGoogle Scholar
• WATKINS G, DOUGLAS-JONES A, BRYCE R, MANSEL RE, JIANG WG: Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fatty Acids. (2005) 72:267-272.
   PubMed Web of Science ®Google Scholar
• KATO Y, NAGASHIMA Y, BABA Y et al.: Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int. J. Mol. Med. (2005) 16:263-268.
   PubMedGoogle Scholar
• RICH JN, HANS C, JONES B et al.: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. (2005) 65:4051-4058.
   PubMed Web of Science ®Google Scholar
• WANG CS, LIN KH, CHEN SL, CHAN YF, HSUEH S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br. J. Cancer. (2004) 91:1924-1930.
   PubMed Web of Science ®Google Scholar
• YAMASHITA K, UPADHAY S, MIMORI K, INOUE H, MORI M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. (2003) 97:2412-2419.
   PubMed Web of Science ®Google Scholar
• YAMANAKA M, KANDA K, LI NC et al.: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J. Urol. (2001) 166:2495-2499.
   PubMed Web of Science ®Google Scholar
• SCHILLING U, FRIEDRICH EA, SINN H, SCHRENK HH, CLORIUS JH, MAIER-BORST W: Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part II. In vivo studies. Int. J. Rad. Appl. Instrum. B. (1992) 19:685-695.
   PubMedGoogle Scholar
• SAGE H, JOHNSON C, BORNSTEIN P: Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. (1984) 259:3993-4007.
   PubMed Web of Science ®Google Scholar
• SAGE H: Culture shock: Selective uptake and rapid release of a novel serum protein by endothelial cells in vitro. J. Biol. Chem. (1986) 261:7082-7092.
   PubMedGoogle Scholar
• VUONG T, FRANKEL T, LABAO E, SOON-SHIONG P, DESAI N: SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) versus Taxol. 96th Annual Meeting of the American Association for Cancer Research. Anaheim/Orange County, CA, USA. April (2005) PO. TB18.
   Google Scholar
• DESAI N, TRIEU V, YAO R et al.: SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) versus Taxol. Breast Cancer Res. Treat. (2004) 88(Suppl. 1):26-27 (plus poster) Abstr. 206.
   Google Scholar
• IBRAHIM NK, DESAI N, LEGHA S et al.: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. (2002) 8:1038-1044.
   PubMed Web of Science ®Google Scholar
• SPARREBOOM A, SCRIPTURE CD, TRIEU V et al.: Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. (2005) 11:4136-4143.
   PubMed Web of Science ®Google Scholar
• IBRAHIM NK, SAMUELS B, PAGE R et al.: Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. (2005) 23:6019-6026.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ JM, GELMON K, BONTENBAL M et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. (1996) 14:1858-1867.
   PubMed Web of Science ®Google Scholar
• GRADISHAR WJ, TJULANDIN S, DAVIDSON N et al.: Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J. Clin. Oncol. (2005) 23:7794-7803.
   PubMed Web of Science ®Google Scholar
• THERASSE P, ARBUCK SG, EISENHAUER EA et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. (2000) 92:205-216.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, BERRY D, CIRRINCIONE C et al.: CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. (2004) American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, Post-Meeting Edition (2004) 22(Suppl.):6s (Abstr. 512).
   Google Scholar
• GREEN MC, BUZDAR AU, SMITH T et al.: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J. Clin. Oncol. (2005) 23:5983-5992.
   PubMed Web of Science ®Google Scholar
• NYMAN DW, CAMPBELL KJ, HERSH E et al.: A Phase I and pharmacokinetics trial of ABI-007, a novel formulation of paclitaxel stabilized with human serum albumin, administered weekly for 3 doses every 4 weeks in patients with advanced, non-hematologic malignancies. J. Cancer Res. (2005) 23:7785-7793.
   Google Scholar
• DAMASCELLI B, CANTÙ G, MATTAVELLI F et al.: Intra-arterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity. Cancer (2001) 92:2592-2602.
   PubMed Web of Science ®Google Scholar
• DAMASCELLI B, PATELLI GL, LANOCITA R et al.: A novel intra-arterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am. J. Roentgenol. (2003) 181:253-260.
   PubMed Web of Science ®Google Scholar
• DESAI N, TRIEU V, YAO R et al.: Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (ABI-007) by gp60-receptors: a pathway inhibited by Taxol. Breast Cancer Res. Treat. (2004) 88(Suppl. 1):65 (plus poster) Abstr. 1071.
   Google Scholar
• FANG J, SAWA T, MAEDA H: Factors and mechanism of ‘EPR’ effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. (2003) 519:29-49.
   PubMed Web of Science ®Google Scholar